Comparison of Delta-8-THC to Ondansetron in the Prevention of Acute Nausea From Moderately Emetogenic Chemotherapy

NCT00285051 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

6

Enrollment

INDUSTRY

Sponsor class

Stopped Study drug expiry date not extended

Conditions

Cancer

Interventions

DRUG: inhaled delta-8-THC 300mcg or 600mcg per dose

Sponsor

Rafa Laboratories

Collaborators

[object Object]